Klin Padiatr 2017; 229(03): 147-167
DOI: 10.1055/s-0043-103086
Diagnostic and Treatment Recommendation
© Georg Thieme Verlag KG Stuttgart · New York

2017 GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic Tumors

2017 GPOH Empfehlungen für Diagnostik und Therapie von Patienten mit neuroblastischen Tumoren
Thorsten Simon
1  Department of Pediatric Oncology and Hematology, University Hospital, University of Cologne
,
Barbara Hero
1  Department of Pediatric Oncology and Hematology, University Hospital, University of Cologne
,
Johannes H. Schulte
2  Department of Pediatric Oncology and Hematology, Charité University Hospital Berlin
,
Hedwig Deubzer
2  Department of Pediatric Oncology and Hematology, Charité University Hospital Berlin
,
Patrick Hundsdoerfer
2  Department of Pediatric Oncology and Hematology, Charité University Hospital Berlin
,
Dietrich von Schweinitz
3  Department of Pediatric Surgery, Dr. von Hauner’sches Kinderspital, LMU Munich
,
Jörg Fuchs
4  Department of Pediatric Surgery and Pediatric Urology, University Hospital Tübingen
,
Matthias Schmidt
5  Department of Nuclear Medicine, University Hospital, University of Cologne
,
Vikas Prasad
6  Department of Nuclear Medicine, Charité University Hospital Berlin
,
Barbara Krug
7  Department of Radiology, University Hospital, University of Cologne
,
Beate Timmermann
8  Clinic for Particle Therapy, Westdeutsches Protonentherapiezentrum, University Hospital Essen
,
Ivo Leuschner
9  Kiel Pediatric Tumor Registry, Dept. for Pediatric Pathology, University Hospital of Schleswig-Holstein, Campus Kiel
,
Matthias Fischer
10  Department of Experimental Pediatric Oncology, University Hospital, University of Cologne
,
Thorsten Langer
11  Pediatric Oncology and Hematology, University Hospital Schleswig-Holstein, Campus Lübeck
,
Kathy Astrahantseff
2  Department of Pediatric Oncology and Hematology, Charité University Hospital Berlin
,
Frank Berthold
1  Department of Pediatric Oncology and Hematology, University Hospital, University of Cologne
,
Holger Lode
12  Department of Pediatrics and Pediatric Oncology and Hematology, University Medicine Greifswald
,
Angelika Eggert
2  Department of Pediatric Oncology and Hematology, Charité University Hospital Berlin
› Author Affiliations
Further Information

Publication History

Publication Date:
30 May 2017 (online)

Abstract

The clinical course of neuroblastoma is more heterogeneous than any other malignant disease. Most low-risk patients experience regression after limited or even no chemotherapy. However, more than half of high-risk patients die from disease despite intensive multimodal treatment. Precise patient characterization at diagnosis is key for risk-adapted treatment. The guidelines presented here incorporate results from national and international clinical trials to produce recommendations for diagnosing and treating neuroblastoma patients in German hospitals outside of clinical trials.